A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer

Gynecologic Oncology

Volumn 67, Issue 2, 1997, Pages 137-140

  Seewaldt, Victoria L ^a   Cain, Joanna M ^b   Goff, Barbara A ^a   Tamimi, Hisham ^a   Greer, Benjamin ^a   Figge, David ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ADULT; AGED; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RISK; CLINICAL ARTICLE; DISEASE ASSOCIATION; EPITHELIUM CELL; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HUMAN; INTESTINE NECROSIS; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR;

EID: 0031281414     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4842     Document Type: Article

References (15)

1. Wingo P A, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin. 45:1995;8-20.
2. Thigpen J T, Blessing J A, Vance R B, Lambuth B W. Chemotherapy in ovarian carcinoma: present role and future prospects. Semin Oncol. 16:1989;58-65.
3. Seewaldt V, Greer B, Tamimi H, Figge D, Brown W, Cain J. Bowel perforation following Taxol in heavily pre-treated ovarian cancer patients. J Clin Oncol. 11:1993;1198.
4. Pestalozzi B C, Sotos G A, Choyke P L, Fisherman J S, Cowan K H, O'Shaughnessy J A. Typhilitis resulting from treatment with Taxol and doxorubicin in patients with metastatic breast cancer. Cancer. 71:1993;1797-1800.
5. National Institute of Health, May 3, 1994.
6. Rose P G, Piver M S. Intestinal perforation secondary to paclitaxel. Gynecol Oncol. 57:1995;270-272.
7. Schiff P, Faut J, Horowitz S. Promotion of microtubule assembly in vitro by taxol. Nature. 277:1979;665-667.
8. Rowinsky E K, Cazenave L A, Donehower R C. Taxol: a novel investigational anti-microtubule agent. J Natl Cancer Inst. 82:1990;1247-1259.
9. McGuire W P, Rowinsky E K, Rosenshein N B. Taxol: a unique anti-neoplastic agent with significant activity in advanced ovarian epithelial neoplasm. Ann Int Med. 111:1989;273-297.
10. Thigpen T, Blessing J, Ball H, Hummel S, Barret R. Phase II trial of Taxol as second-line therapy for advanced ovarian adenocarcinoma: A Gynecologic Oncology Group Study. Proc Am Soc Clin Oncol. 10:1992;1748-1753.
11. Trimble E L, Adams D V, Hawkins M J, Friedman M A, Fisherman J S, Christian M C, Canetta R, Onetto N, Hayn R, Arbuck S G. Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1,000 patient registered to National Cancer Institute treatment referral center 9103. J Clin Oncol. 11:1993;2405-2410.
12. Rubin S C, Benjamin I, Hoskins W J. Intestinal surgery. Gynecol Oncol. 34:1988;30-33.
13. Hruban R H, Yardly J H, Donehower R C. Taxol toxicity. Cancer. 63:1989;1944-1950.
14. Manfredi J J, Horwitz S B. Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther. 25:1984;83-125.
15. Rowinsky E K, Donehower R C, Jones R J. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res. 48:1988;4093-4100.